COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE)
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 2, before-and-after interventional study is to investigate the effect
of colchicine treatment on serum biomarkers of inflammation in patients with a history of
stroke and atherosclerosis.
Participants meeting inclusion criteria will have blood samples drawn at baseline, will be
dispensed colchicine 0.5mg daily for a treatment period of 30 days and have blood samples
drawn again at follow-up. All blood samples will be analysed for a panel of inflammatory
blood markers and the change in blood inflammatory markers from baseline to end of treatment
will be calculated.